Sanofi buys rights to Principia’s BTK inhibitor
admin 10th November 2017 Uncategorised 0Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.
More: Sanofi buys rights to Principia’s BTK inhibitor
Source: News